Lexicon Pharmaceuticals

Update in progress

LXRX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for human disease. It advances sotagliflozin for hypertrophic cardiomyopathy and Zynquista for type 1 diabetes, and commercializes INPEFA to reduce cardiovascular death and heart failure events in adults with heart failure, type 2 diabetes, CKD, and related risks. It also develops LX9851 for obesity and pilavapadin for neuropathic pain, with collaborations with Viatris and Bristol Myers Squibb. Incorporated in 1995, based in The Woodlands, Texas.

Company score

Sentiment: 0.29; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.12; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive